Abstract:9089 Background: Platinum-based chemotherapy is the backbone of treatment for advanced non-small cell lung cancer. Cisplatin has well-known side effects such as gastrointestinal reaction and fatigue, and nedaplatin was developed to be an alternative platinum with less toxicity. We aimed to compare nedaplatin plus pemetrexed was non-inferior to cisplatin plus pemetrexed as first-line chemotherapy for advanced EGFR/ALK-negative lung adenocarcinoma. Methods: We did an open-label, randomized, phase III trial at 15 centers in China. Advanced lung adenocarcinoma patients with EGFR/ALK-negative status were randomly assigned to receive nedaplatin 90 mg/m 2 or cisplatin 75 mg/m 2 plus pemetrexed 500 mg/m 2 for 6 cycles as first-line treatment, and pemetrexed maintenance for those without progressive disease. The primary endpoint was progression-free survival (PFS), non-inferiority was shown if the upper limit of the 95% CI for the hazard ratio (HR) of PFS did not exceed 1.30. Secondary endpoints included objective response, overall survival and toxicity. This trial is registered with ClinicalTrials.gov, number NCT02607592. Results: Between Sep 2015 and May 2021, 218 patients were randomized to nedaplatin group (n = 111) or cisplatin group (n = 107). In the intention-to-treat population, median PFS time was 6.87 months (95%CI, 5.25 to 8.49) in the nedaplatin group and 5.53 months (95%CI, 4.57 to 6.50) in the cisplatin group, with a HR of 0.76 (95%CI, 0.56 to 1.03, p= 0.078). In the per-protocol population (nedaplatin group, n = 105; cisplatin group, n = 94), median PFS time was 6.87 months (95%CI, 5.36 to 8.37) and 5.20 months (95%CI, 4.03 to 6.37) respectively, with a HR of 0.76 (95%CI, 0.56 to 1.03, p= 0.082). Overall response rate was 41.9% in nedaplatin group and 26.6% in cisplatin group ( p= 0.026). A significantly higher frequency of any grade nausea and vomiting (51[53.68%] of 95 in the cisplatin group vs 30[28.04%] of 107 in the nedaplatin group, p< 0.001), fatigue (37[38.95%] vs 27[25.23%], p= 0.037), and constipation (15[15.79%] vs 5[4.67%], p= 0.008) were reported in the cisplatin group compared with the nedaplatin group. Higher rate of grade 3/4 nausea and vomiting was observed in cisplatin group (10[10.53%] vs 0, p= 0.001). Patients in the nedaplatin group had higher frequency of thrombocytopenia but without statistical significance (any grade: 28[26.17%] of 107 in the nedaplatin group vs17[17.89%] of 95 in the cisplatin group, p= 0.158; grade 3/4: 8[7.48%] in the nedaplatin group vs 3[3.16%] in the cisplatin group, p= 0.177). Conclusions: Our findings show that nedaplatin plus pemetrexed is not inferior to cisplatin plus pemetrexed in progression-free survival, with less toxicities, which represents an alternative chemotherapy regimen for EGFR/ALK-negative advanced lung adenocarcinoma. Clinical trial information: NCT02607592.

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Efficacy and Safety of Pemetrexed/cisplatin Versus Gemcitabine/cisplatin As First-Line Treatment in Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

[Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Pemetrexed Plus Platinum or Gemcitabine Plus Platinum for Advanced Non-Small Cell Lung Cancer: Final Survival Analysis from A Multicentre Randomized Phase Ii Trial in the East Asia Region and A Meta-Analysis

Clinical observation of efficacy and safety of pemetrexed plus platinum as the first-line chemotherapy with advanced non-squamous non-small cell lung cancer

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

Clinical Observation and Prognostic Analysis of Pemetrexed Plus Platinum As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer.

Pemetrexed As the First-Line Therapy for Chinese Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer.

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel As First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial.

MA 03.03 Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung

Study of Gefitinib and Pemetrexed As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

Full-dose Pemetrexed Plus Cisplatin Combined with Concurrent Thoracic Radiotherapy for Previously Untreated Advanced Nonsquamous Non-Small Cell Lung Cancer.

The clinical effects of pemetrexed or docetaxel combined with cisplatin as the first line treatment for advanced lung adenocarcinoma

A Randomized Controlled Clinical Trial on Irinotecan/cisplatin Versus Gemcitabine/cisplatin As the First-Line Treatment in Advanced Non-Small Cell Lung Cancer

Clinical Effectiveness and Clinical Toxicity Associated with Platinum-Based Doublets in the First-Line Setting for Advanced Non-Squamous Non-Small Cell Lung Cancer in Chinese Patients: a Retrospective Cohort Study.

Nedaplatin plus pemetrexed or cisplatin plus pemetrexed as first-line chemotherapy for EGFR/ALK-negative advanced lung adenocarcinoma (NACA): A multicenter, open-label, non-inferiority, randomized, phase III trial.

An Open-Label, Randomized, Multicenter, Phase III Study of S-1 and Cisplatin Versus Docetaxel and Cisplatin in Patients with Untreated Advanced Non-Small-cell Lung Cancer.

Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial